INVO Bioscience amends merger with NAYA; extends deadline to Oct 14, revised consideration

INVO Fertility, Inc.

NAYA purchased 27,500 Series A preferred shares for $137,500 on Sept 16, 2024 per Securities Purchase Agreement.
NAYA may buy up to additional 72,500 Series A shares for $362,500 before or at closing; prior breaches waived.
Revised merger consideration: ≤19.9% of INVO common stock pre-merger plus new Series C convertible preferred.
After stockholder approval, Series C converts to common representing ~60.1% of INVO outstanding shares.
NAYA to transfer 85% of common stock payment shares to secured lender Five Narrow Lane LP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.